应对转移性三阴性乳腺癌免疫疗法的实际挑战
Luca Licata1, Maria Vittoria Dieci2, Carmine De Angelis3
1Department of Medical Oncology, San Raffaele Hospital, Milan, Italy; School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy.
Cancer treatment reviews
|May 22, 2024
概括
免疫疗法,包括免疫检查点抑制剂,是三阴性乳腺癌的标准治疗方法. 本指南解决了临床医生优化其使用的实际问题,并确定了未来研究的领域.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 免疫疗法已成为癌症治疗的基石,特别是三阴性乳腺癌 (TNBC).
- 目前的批准涵盖了TNBC的早期和高级阶段.
研究的目的:
- 为临床医生提供关于优化乳腺癌免疫检查点抑制剂 (ICI) 治疗的实际指导.
- 确定该领域未来研究的关键问题.
主要方法:
- 这份手稿综合了当前的临床实践和研究成果.
- 它解决了关键临床试验未完全涵盖的实际问题.
主要成果:
- 免疫疗法在TNBC管理中提供了显著的好处.
- 临床试验提供了一个基础,但实际应用需要进一步澄清.
结论:
- 优化ICI在乳腺癌中的使用需要解决实际的临床问题.
- 进一步的研究对于完善免疫疗法策略和改善患者治疗结果至关重要.
相关概念视频
01:27Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K